Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 8c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PCVX
2. PTC
3. NVDA
4. SPY
5. META
6. MSFT
7. GMAB
8. BETR
9. BBIO
10. USO

Go back to Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 8c, Revenues Beat

Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

May 1, 2019 7:30 AM EDT

Successfully Completed $70 Million Financing

On Track for Multiple Data Readouts for Clinical-Stage Programs in 2019 and 2020

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2019 and provided an update on recent accomplishments and upcoming events.

Our first quarter accomplishments mark important progress against our strategic priorities for 2019, said Nancy... More